Hologic Inc., a leading developer of women's health technologies, disclosed on Monday that its Chief Executive Officer, Steve MacMillan, intends to retire upon the completion of the company's pending sale to private equity giants Blackstone and TPG. The transaction, valued at approximately $18.3 billion including assumed debt, has received all necessary regulatory approvals and is now slated to close on or about April 7, 2026.
The announcement marks the approaching conclusion of a major deal in the medical device sector and signals the end of MacMillan's tenure at the helm of the publicly traded company. Shareholders previously voted to approve the merger in February. When initially unveiled in October, the acquisition was noted as the largest medical-device transaction since Boston Scientific's purchase of Guidant two decades prior.
Final Trading and Delisting Schedule
Nasdaq has designated April 6 as the anticipated final trading day for Hologic shares. Trading is expected to be halted following the after-hours session, which concludes around 7:50 p.m. Eastern Time. Provided the merger is consummated, the stock will remain halted on April 7 and will be formally delisted from the exchange effective April 8.
This timeline is critical for investors, as the buyout consortium is offering $76.00 in cash per share, supplemented by a non-tradable contingent value right (CVR). This CVR represents a potential additional payment contingent upon the financial performance of Hologic's Breast Health division. Specifically, it could yield up to an extra $3.00 per share if the unit meets predefined revenue targets for fiscal years 2026 and 2027.
Market Reaction and Leadership Transition
In late trading on Monday, Hologic shares were exchanging hands near $76.01, aligning closely with the cash component of the offer and indicating strong market confidence that the deal will close as scheduled. The board of directors plans to appoint a new chief executive following the transaction's completion.
MacMillan, 62, who has served as President and CEO since late 2013 and as Chairman since 2015, stated, "Leading Hologic has been the greatest honor and privilege of my career." Amy Wendell, the board's lead independent director, praised his leadership in orchestrating a "dramatic turnaround," guiding the company through significant growth, its response to the COVID-19 pandemic, and the sale process itself.
Financial Performance and Competitive Landscape
The buyers are acquiring a business that continues to exhibit growth, albeit with mixed segment performance. Hologic recently reported quarterly revenue of $1.05 billion, a 2.5% year-over-year increase. While surgical sales surged 8.7%, molecular diagnostics revenue declined 3.5%, reflecting reduced demand for COVID-19 tests and certain legacy assays for sexually transmitted infections.
In its latest annual report, Hologic identified Roche Diagnostics and Abbott Laboratories as primary competitors within the molecular diagnostics space. Blackstone and TPG have framed their acquisition as a strategic investment to support Hologic's product pipeline and expansion initiatives. Analyst Ryan Zimmerman of BTIG characterized the offer as "fair for all parties," adding that it generally bolstered sentiment within the med-tech sector by expanding the universe of potential acquirers.
Remaining Considerations and Risks
While nearing the finish line, the deal is not without remaining conditions. Hologic reiterated that completion remains subject to standard closing conditions. The company's filings also caution that payouts to CVR holders could be reduced if the Breast Health unit's targets are not fully achieved. Furthermore, the change in ownership may create challenges for employee retention and maintaining key business relationships.
Post-merger, Hologic will cease to be a publicly listed company, but its corporate headquarters will remain in Marlborough, Massachusetts, and its operations will continue under the Hologic brand name as a privately held entity owned by the private equity consortium.
